Fmoc-alpha-Me-L-Phe-OH*1.5H2O

Fmoc-alpha-Me-L-Phe-OH·1.5H2O is an Fmoc-protected, L-configured phenylalanine derivative bearing an alpha-methyl substituent, where the stereogenic center at the amino acid alpha-position is fixed to the L-series configuration. The structure combines an N-(9H-fluoren-9-ylmethoxycarbonyl) carbamate with a free carboxylic acid, enabling orthogonal reactivity during protected amino acid synthesis and subsequent peptide coupling. The alpha-methyl substitution increases steric demand around the backbone, which can influence coupling kinetics and the conformational preferences of resulting peptides and peptidomimetics. The hydrate form (1.5 H2O) is consistent with a solid-state water association that can affect handling and dissolution behavior while preserving the underlying functional group pattern required for Fmoc deprotection and amide bond formation.

1. Peptide Synthesis

Fmoc-alpha-Me-L-Phe-OH·1.5H2O is used in automated and manual solid-phase peptide synthesis as an Fmoc-protected amino acid building block with a free C-terminal carboxylic acid for reliable amide bond formation. The Fmoc carbamate supports standard orthogonal N-protection, while the L-configuration and the alpha-methyl stereocenter provide a defined chiral backbone element that can be incorporated into peptides to probe how alpha-substitution alters local structure. Side-chain reactivity is minimal beyond the benzyl phenyl group, so coupling and subsequent deprotection steps can focus on backbone assembly rather than additional functional-group compatibility constraints. Downstream, peptides prepared with this residue can serve as substrates or reference materials for analytical characterization of peptide coupling outcomes and stereochemical fidelity in amino acid derivative libraries.

2. Peptidomimetics And SAR

Fmoc-alpha-Me-L-Phe-OH·1.5H2O is applicable to peptidomimetic construction and structure-activity relationship studies where incorporation of an alpha-methylated phenylalanine residue can modulate backbone flexibility and protease susceptibility patterns. The alpha-methyl substituent and the preserved L-configuration create a stereodefined, sterically biased amino acid unit that can be introduced into peptide analogs while maintaining the aromatic side chain as a hydrophobic recognition element. The Fmoc-protected nitrogen enables controlled assembly of analog series on-resin, supporting systematic variation of neighboring residues to map how stereochemistry and steric effects influence binding motifs. Resulting peptide analogs can be used as chemically defined SAR reagents for fragment-based optimization workflows and for comparative studies of conformational effects across closely related scaffolds.

3. Protected Amino Acid Chemistry

Fmoc-alpha-Me-L-Phe-OH·1.5H2O functions as a protected amino acid derivative for intermediate preparation in synthetic organic chemistry, combining an Fmoc-protected amine with a carboxylic acid handle for activation and downstream transformations. The orthogonal protection strategy allows selective removal of the Fmoc group under standard deprotection conditions while retaining the carboxyl functionality for coupling or for conversion into activated derivatives such as acid chlorides, mixed anhydrides, or activated esters in solution-phase workflows. The alpha-methyl stereocenter provides a chiral building block suitable for stereochemically controlled peptide construction and for generating diastereomerically defined analogs when incorporated into larger synthetic sequences. Hydrate-associated handling considerations can be leveraged to tune dissolution and processing behavior in fine chemical synthesis routes that require reproducible solid-state inputs.

4. Chemical Biology Labeling

Fmoc-alpha-Me-L-Phe-OH·1.5H2O can be incorporated into chemically defined peptides used in chemical biology research where aromatic phenylalanine residues provide stable anchors for subsequent derivatization strategies. The Fmoc-protected backbone enables preparation of labeled peptide probes by standard peptide assembly, after which the resulting peptide can be functionalized at termini or at additional side-chain handles introduced elsewhere in the sequence. The alpha-methylated residue can influence peptide conformation and proteolytic stability, which may improve the chemical persistence of probes used for binding studies, competition assays, or mechanistic investigations. The defined stereochemistry at the alpha-position supports reproducible probe behavior across analog panels prepared for molecular recognition and pathway interrogation.

5. Pharmaceutical Manufacturing Intermediate

Fmoc-alpha-Me-L-Phe-OH·1.5H2O is suitable for pharmaceutical manufacturing-oriented peptide intermediate preparation, where Fmoc-protected amino acid inputs are commonly used in controlled solid-phase synthesis of peptide-based actives and process intermediates. The compound's combination of an Fmoc-protected N-terminus and a carboxylic acid enables straightforward incorporation into peptide sequences during manufacturing-scale assembly, while the L-configured alpha-methyl stereocenter supports consistent stereochemical outcomes in the final active or intermediate. The aromatic side chain contributes predictable hydrophobic character without introducing additional reactive groups that could complicate process impurity profiles. The hydrate form can be managed as part of solid handling and formulation of feed materials for reproducible downstream peptide construction in industrial chemical manufacturing settings.

1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

2. Cationic cell-penetrating peptides are potent furin inhibitors

3. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

4. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

5. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma